Last reviewed · How we verify
Symtuza® (TAF/FTC/DRV/c)
Symtuza is a fixed-dose combination antiretroviral that inhibits HIV reverse transcriptase and protease to prevent viral replication.
Symtuza is a fixed-dose combination antiretroviral that inhibits HIV reverse transcriptase and protease to prevent viral replication. Used for HIV-1 infection in treatment-naïve and treatment-experienced adults.
At a glance
| Generic name | Symtuza® (TAF/FTC/DRV/c) |
|---|---|
| Sponsor | Fundacion SEIMC-GESIDA |
| Drug class | Antiretroviral combination (NRTI/INSTI class with protease inhibitor) |
| Target | HIV reverse transcriptase, HIV protease, CYP3A4 |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease / Virology |
| Phase | FDA-approved |
Mechanism of action
The combination contains tenofovir alafenamide (TAF) and emtricitabine (FTC), which are nucleotide/nucleoside reverse transcriptase inhibitors that block HIV reverse transcriptase, plus darunavir (DRV), a protease inhibitor that prevents HIV protease from cleaving viral polyproteins. Cobicistat (c) is a pharmacokinetic booster that inhibits CYP3A4 to increase darunavir exposure.
Approved indications
- HIV-1 infection in treatment-naïve and treatment-experienced adults
Common side effects
- Diarrhea
- Nausea
- Headache
- Rash
- Elevated lipids
- Renal function changes
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Symtuza® (TAF/FTC/DRV/c) CI brief — competitive landscape report
- Symtuza® (TAF/FTC/DRV/c) updates RSS · CI watch RSS
- Fundacion SEIMC-GESIDA portfolio CI